Focused On-demand Library for Cation channel sperm-associated targeting subunit tau

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q53TS8

UPID:

CTSRT_HUMAN

Alternative names:

Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 11 protein; C2 calcium-dependent domain-containing protein 6

Alternative UPACC:

Q53TS8; C9IZH7; E9PGG4; Q8NCN6; Q96LN4

Background:

The Cation channel sperm-associated targeting subunit tau, also known as Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 11 protein and C2 calcium-dependent domain-containing protein 6, plays a crucial role in sperm cell hyperactivation. This process is essential for sperm motility, a key factor in the successful fertilization of an egg. The protein is an auxiliary component of the CatSper complex, facilitating the targeting and trafficking of this complex into the quadrilinear nanodomains of elongating flagella.

Therapeutic significance:

Spermatogenic failure 68, a disorder characterized by globozoospermia and linked to variants affecting this protein, highlights its critical role in male fertility. Understanding the role of Cation channel sperm-associated targeting subunit tau could open doors to potential therapeutic strategies for treating infertility issues related to sperm motility.